Ximluci

Ximluci (ranibizumab) is an intravitreal injection used to treat eye conditions like wet age-related macular degeneration and diabetic macular edema. This VEGF inhibitor helps reduce abnormal blood vessel growth in the retina. Suitable for patients seeking targeted retinal therapy.

Ximluci (ranibizumab) is prescribed to address vision problems caused by retinal disorders. It helps manage conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME), where abnormal blood vessels grow in the retina. By targeting vascular endothelial growth factor (VEGF), it supports maintaining or improving vision in affected individuals.

After administration, Ximluci works locally within the eye to reduce swelling and prevent further damage to the retina. Patients may notice improved clarity in vision over time, though individual responses vary. The treatment aims to stabilize or slow the progression of retinal diseases rather than provide immediate symptomatic relief.

Ximluci is administered by a healthcare professional via intravitreal injection, requiring sterile conditions. Patients should inform their doctor of any eye infections, recent surgeries, or allergies before treatment. Regular eye exams are recommended to monitor progress and detect any changes in retinal health.

No direct drug interactions are reported for Ximluci, as it is administered locally into the eye. However, patients using other intravitreal therapies or blood thinners should discuss their full medication list with their doctor. Combining treatments may require adjusted monitoring schedules.